Annis Gardner Whiting Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-221
Closed -$17.7K – 623
2026
Q1
$17.7K Buy
221
+66
+43% +$5.44K ﹤0.01% 768
2025
Q4
$13.2K Buy
155
+32
+26% +$2.63K ﹤0.01% 723
2025
Q3
$9.57K Buy
123
+18
+17% +$1.41K ﹤0.01% 715
2025
Q2
$8.21K Hold
105
– – ﹤0.01% 770
2025
Q1
$7.61K Sell
105
-41
-28% -$2.94K ﹤0.01% 580
2024
Q4
$10.8K Buy
146
+41
+39% +$2.87K ﹤0.01% 525
2024
Q3
$6.93K Hold
105
– – ﹤0.01% 599
2024
Q2
$9.7K Hold
105
– – ﹤0.01% 690
2024
Q1
$10K Hold
105
– – ﹤0.01% 671
2023
Q4
$8.01K Hold
105
– – ﹤0.01% 496
2023
Q3
$7.28K Buy
+105
New +$8.44K ﹤0.01% 493

Other funds holding EW

Annis Gardner Whiting Capital Advisors's EW Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 221 shares — an estimated $17.7K sold.

Annis Gardner Whiting Capital Advisors first reported a position in EW in Q3 2023 and held it in 11 quarters. The position peaked at $17.7K in Q1 2026. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 221 Edwards Lifesciences shares in Q2 2026, an estimated $17.7K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Edwards Lifesciences in Q3 2023 and held it in 11 quarters.
  • Annis Gardner Whiting Capital Advisors's Edwards Lifesciences position peaked at $17.7K in Q1 2026.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.